The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a “real life” retrospective multicenter experience of the Rete Ematologica Pugliese (REP)

Annals of Hematology

Volumn 95, Issue 2, 2016, Pages 239-244

  Mazza, Patrizio ^a   Minoia, Carla ^a   Melpignano, Angela ^b   Polimeno, Giuseppe ^c   Cascavilla, Nicola ^d   Di Renzo, Nicola ^e   Specchia, Giorgina ^f  

^a San Giuseppe Moscati Hospital   (Italy)

^b Antonio Perrino Hospital   (Italy)

^c MIULLI GENERAL HOSPITAL   (Italy)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^e VITO FAZZI HOSPITAL   (Italy)

^f UNIVERSITY OF BARI   (Italy)

Author keywords

Immune thrombocytopenia (ITP); Splenectomy; Thrombopoietin receptor agonists

Indexed keywords

AMINOTRANSFERASE; ELTROMBOPAG; IMMUNOGLOBULIN; METHYLPREDNISOLONE; RITUXIMAB; ROMIPLOSTIM; BENZOIC ACID DERIVATIVE; FC RECEPTOR; HYBRID PROTEIN; HYDRAZINE DERIVATIVE; MPL PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR;

ADULT; AGE; AGED; ARTHRALGIA; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GASTRITIS; HEADACHE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MAJOR BLEEDING; MAJOR CLINICAL STUDY; MALE; MINOR BLEEDING; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SIDE EFFECT; SPLENECTOMY; THROMBOSIS; TREATMENT RESPONSE; AGONISTS; CLINICAL TRIAL; COHORT ANALYSIS; HOSPITAL; ITALY; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; TRENDS;

AGED; BENZOATES; COHORT STUDIES; FEMALE; HOSPITALS; HUMANS; HYDRAZINES; ITALY; MALE; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PYRAZOLES; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; THROMBOPOIETIN;

EID: 84955183941     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-015-2556-z     Document Type: Article

References (14)

1. Stasi R (2011) Pathophysiology and therapeutics options in primary immune thrombocytopenia. Blood Transfus 9:262–273
2. Neunert CE, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA (2011) The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 117:4190–4207
3. Neunert CE (2013) Individualized treatment for immune thrombocytopenia: predicting bleeding risk. Semin Hematol 50:S55–57
4. Rodeghiero, F., Stasi, R., Gernsheimer, T., Michel, M., Provan, D., Arnold, D.M., Bussel, J.B., Cines, D.B., Chong, B.H., Cooper, N., Godeau, B., Lechner, K., Mazzucconi, M.G., McMillan, R., Sanz, M.A., Imbach, P., Blanchette, V., Kühne, T., Ruggeri, M. & George, J.N.(2998) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood113(11):2386–93.
5. Choe MJ, Packer CD (2015) Severe romiplostim-induced rebound thrombocytopenia after splenectomy for refractory ITP. Ann Pharmacother 49:140–144
6. Cervinek, L., Majer, J.& Doubek, M. (2015) Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults. International Journal of Hematology, (Epub ahead print).
7. Mahevas M, Fain O, Ebbo M, Roudot-Thoraval F, Limal N, Khellaf M, Scleinitz N, Bierling P, Languille L, Godeau B, Michel M (2014) The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. Br J Haematol 165:865–869
8. Bao W, Bussel JB, Heck S (2010) Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietin agents. Blood 116:4639–4645
9. Ghadaki B, Nazi I, Kelton JG, Arnold DM (2013) Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists. Transfusion 58:395–398
10. Kuter DJ, Bussel JB, Lyons RM (2010) Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. Lancet 371:395–403
11. Kuter DJ, Rummel M, Boccia R (2010) Romiplostim or standard of care in patients with immune thrombocytopenic purpura. N Engl J Med 357:2237–2247
12. Polverelli N, Palandri F, Iacobucci I, Catani L, Martinelli G, Vianelli N (2013) Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms. Br J Haematol 161:142–144
13. D’Arena G, Guariglia R, Mansueto G, Martorelli MC, Pietrantuono G, Villani O, Lerose R, Musto P (2013) No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura. Blood 121:1240–1242
14. Kashiwagi H, Tomiyama Y (2015) Recent advances in pathophysiology and treatment of immune thrombocytopenia. Rinsho Kesueki 56:177–184